Related Experiment Videos
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Arnaud Chiolero1, Marc P Maillard, Michel Burnier
1Division of Hypertension and Vascular Medicine, Department of Medicine, CHUV, CH-1011 Lausanne, Switzerland.
Abstract:
Since 1998, two selective inhibitors of COX-2 have been approved in many countries for the treatment of rheumatoid arthritis, osteoarthritis and acute pain. These new drugs have a significantly reduced gastrointestinal toxicity when compared with non-selective COX inhibitors. However, the results of two large clinical trials conducted in patients with osteoarthritis and rheumatoid arthritis have recently raised some concerns regarding the cardiovascular safety of these new drugs. The purpose of this paper is to review the potential mechanisms whereby selective COX-2 inhibitors could increase the cardiovascular risk of patients and to analyse the data indicating that this clinical risk indeed exists. The authors' analysis shows that even though there are pathophysiological mechanisms which could explain why selective COX-2 inhibition might increase the cardiovascular risk in patients, the actual level of evidence demonstrating that the risk is indeed increased is weak. Because of the importance of the issue, additional studies must be conducted with this class of agents. Meanwhile, it is crucial to emphasise that neither selective COX-2 inhibitors nor conventional NSAIDs replace aspirin in patients with a high cardiovascular risk.
Insights
Selective COX-2 inhibitors offer reduced gastrointestinal toxicity but may pose cardiovascular risks. Current evidence for increased cardiovascular risk is weak, necessitating further research. Aspirin remains crucial for high-risk patients.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Rheumatology
Background:
- Selective COX-2 inhibitors approved since 1998 for arthritis and pain.
- These drugs exhibit lower gastrointestinal toxicity than non-selective COX inhibitors.
- Recent trials raise concerns about the cardiovascular safety of selective COX-2 inhibitors.
Purpose of the Study:
- Review potential mechanisms linking selective COX-2 inhibitors to increased cardiovascular risk.
- Analyze existing data on the clinical cardiovascular risk associated with these drugs.
Main Methods:
- Literature review of pathophysiological mechanisms.
- Analysis of data from large clinical trials.
- Evaluation of cardiovascular safety evidence.
Main Results:
- Pathophysiological mechanisms suggest a potential for increased cardiovascular risk.
- The current level of clinical evidence demonstrating this increased risk is weak.
- Further studies are required to definitively assess cardiovascular safety.
Conclusions:
- Selective COX-2 inhibition may have theoretical cardiovascular risks, but robust clinical evidence is currently lacking.
- Additional research is essential to clarify the cardiovascular safety profile of selective COX-2 inhibitors.
- Selective COX-2 inhibitors and conventional NSAIDs do not substitute for aspirin in patients with high cardiovascular risk.